Stereotaxis Reports 4% Recurring Growth with System Revenue Down Over 50%
Posted on November 13, 2018 by Medtech[y] Staff
Stereotaxis (OTCQX: STXS), reported financial results for the third quarter, showing overall recurring growth of 4% versus the prior year quarter and a reduction in system revenue by over 50%.
Third Quarter and First Nine Months 2018 Financial Results Revenue for the third quarter of 2018 totaled $7.6 million. Recurring revenue was $6.8 million in the third quarter, up 4% from $6.5 million in the prior year quarter. Recurring revenue for the first nine months of 2018 of $21.0 million was up 5% from the first nine months of 2017. System revenue in the third quarter was $0.7 million, down from $1.6 million in the prior year quarter. System revenue in the prior year quarter primarily reflected the shipment of a Niobe® System to an international distributor.
Gross margin in the quarter was $5.9 million, or 78% of revenue, compared to $6.2 million and 76% of revenue in the third quarter of 2017. Operating expenses in the third quarter were $6.0 million, down from $6.1 million in the prior year quarter. Operating loss and net loss in the third quarter were $(0.1) million.
“We continue to make meaningful progress on our strategic innovation initiatives, and expect to be able to publicly showcase our progress in the first half of 2019,” said David Fischel, Chairman and CEO. “We are confident that our innovation strategy is clinically and commercially sound, will provide significant benefits to patients, physicians and hospitals, and will substantially increase Stereotaxis’ financial opportunity.”
Negative free cash flow in the third quarter was ($0.4) million, compared to ($0.6) million in the year ago third quarter. Negative free cash flow for the first nine months of 2018 was ($2.0) million, compared to ($3.9) million in the first nine months of 2017. The negative free cash flow for the first nine months of 2018 represents the strongest performance in nearing breakeven for the company in its history.
“While making significant investments in innovation and commercial infrastructure, our financial discipline has allowed us to reduce cash utilization. The negative free cash flow in the first nine months of 2018 is the closest to breakeven in the history of the Company.”
Cash Balance and Liquidity At September 30, 2018, Stereotaxis had cash and cash equivalents of $11.6 million, no debt, and $3.2 million in unused borrowing capacity on its revolving credit facility, for total net liquidity of $14.8 million.
Full Year 2018 Expectations The Company is reaffirming its expectation of achieving record high annual recurring revenue of approximately $28 million for the full year 2018.
What's Next for Stereotaxis?
The Company continues to expect moderate increases in operating expenses as it invests in strategic innovation initiatives. The benefits of these initiatives are expected to meaningfully contribute to revenue in 2019 and beyond. Stereotaxis’ balance sheet will allow the Company to deliver on its commercial and innovation initiatives over the coming years and reach profitability without the need for additional financings.
“The recurring revenue growth in the quarter positions us to achieve record recurring revenue this year. The development of foundational commercial infrastructure to support the success of robotic electrophysiology practices is best reflected in the recent launch of www.RoboticEP.com, a platform by which our technology and clinical value can be presented in an organized and elegant fashion to the broader community.”
“The medical device industry and healthcare community are rapidly embracing robotics in laparoscopic, orthopedic, and spinal surgery. This was exemplified in the September acquisition of Mazor Robotics by Medtronic. As the pioneer and undisputed leader of robotics in endovascular surgery, Stereotaxis is excited and encouraged by these broader developments. We are confident that endovascular surgery will similarly be transformed by this wave of technological progress.”